<DOC>
	<DOCNO>NCT02694562</DOCNO>
	<brief_summary>The purpose study determine safety local tumor control Embozene TANDEM Microspheres ( 40um TANDEM ) load Irinotecan treat metastatic colorectal carcinoma ( mCRC ) .</brief_summary>
	<brief_title>Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy</brief_title>
	<detailed_description>Colon rectal carcinoma spread liver consider metastatic Stage IV cancer . If metastasize tumor unresectable , current treatment chemotherapy . Transarterial Chemoembolization ( TACE ) consider palliative treatment advance metastatic colorectal carcinoma ( mCRC ) , potential local tumor control . TACE evolve past 8 year include drug-delivery device target deliver drug small microparticles ( DEB-TACE ) . Superselective DEB-TACE potential penetrate deeper tumor 's vasculature reach peripheral grow point . Loading microparticles cytotoxic drug may improve level local tumor control . The MIRACLE III study control , pilot , single center ( Italy ) study 18 subject pretreated non-resectable mCRC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Male Female , age &gt; 18 yr histologically confirm adenocarcinoma colon rectum ( Stage IV ) Presence metastatic disease liver dominant diseasesite define &gt; 80 % tumor body burden confine liver ; le 60 % liver tumor replacement . Subject competent willing provide write informed consent order participate study . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 ChildPugh classification A B7 . Multinodular single nodular tumor 4 cm , patient bilobar disease treat superselectively single session lobes able treat within 3 week . Patient must least one tumor lesion meet follow criterion : lesion accurately measure least one dimension accord Modified Response Evaluation Criteria Solid Tumors ( mRECIST ) criterion . Pretreatment two line chemotherapy contain Fluorouracil ( 5FU ) analogue , oxaliplatin , irinotecan ± bevacizumab ±epidermal growth factor receptor ( EGFR ) inhibitor , indicate , metastatic disease . No invasion blood vessel ( hepatic portal , hepatic vein ) bile duct computerize axial tomography ( CT ) Magnetic Resonance ( MR ) Imaging . Proper blood , liver , renal , heart function : testing result within 2 week registry study follow : 1 . White Blood Cell ( WBC ) &gt; 3,000 cells/mm3 2 . Absolute neutrophil count ≥1500/mm3 3. International Normalized Ratio ( INR ) &lt; 2.0 4 . Partial Thromboplastin Time ( PTT ) &lt; 40 sec 5 . Platelet count &gt; 50,000/mm3 6 . Blood bilirubin &lt; 3.0 mg/dL 7 . Aspartate Aminotransferase ( AST ) and/or Alanine Aminotransferase ( ALT ) within 5 time normal range organ 8 . Serum creatinine &lt; 1.5 mg/dL 9 . Hemoglobin &gt; 8.0 g/dL 10 . Alkaline phosphatase &lt; 630 IU/L 11 . No unstable coronary artery disease recent Myocardial Infarction ( MI ) 12 . Normal electrocardiogram ( ECG ) QT interval &lt; 480 msec within previous 12 month 13 . No current infection require antibiotic therapy 14 . Not anticoagulation suffer know bleed disorder . Measureable disease per mRECIST . Expected survival 3 month ECOG performance status &gt; 2 ; ChildPugh class &gt; 11 point , American Society Anaesthesiologists ' ( ASA ) class 5 . Bilirubin level &gt; 3 mg/dL mCRC within large vessel biliary duct invasion , diffuse hepatocellular carcinoma ( HCC ) extrahepatic spread . Patients follow contraindicated present : 1 . The use irinotecan 2 . MRI CT scan 3 . Hepatic embolization procedure 4 . WBC &lt; 3000 cells/mm3 5. neutrophil &lt; 1500 cells/mm3 6 . Cardiac ejection fraction &lt; 50 % assessed isotopic ventriculography , echocardiography MRI 7 . Elevated serum creatinine ≥ 2.5 mg/dL 8 . Impaired clot test ( platelet count &lt; 50,000/mm3 , PTINR &gt; 2.0 9 . AST and/or ALT &gt; 5x upper limit normal ( ULN ) , great &gt; 250 U/I 10 . Known hepatofugal blood flow . 11 . Arteriovenous shunt 12 . Arterioportal shunt 13 . Main stem portal vein occlusion Women pregnant nursing Allergy iodinate contrast use angiography Tumour burden 50 % liver volume ( Tumor volume small e.g . ≤30 % ) Patients active bacterial , viral ( HIV ) , fungal infection . Other malignancy Any comorbid disease condition event , investigator 's judgment , would place patient undue risk would preclude safe use DEBTACE .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Metastatic Colorectal Carcinoma</keyword>
</DOC>